In Clinical Practice: Overcoming Patient Barriers to PrEP

Volume 1, Issue 2

In this issue:

PrEP — pre-exposure prophylaxis to prevent HIV transmission — is safe, it’s effective, and it’s significantly underused in the U.S.  One key barrier to increased PrEP use is a lack of awareness and acceptance among the patient populations most at-risk for new HIV infection.

In this podcast, Dr. Douglas Krakower from Harvard Medical School takes us into the exam room to translate the new information in his Newsletter Issue into clinical practice.

Take our post-test to claim CME credits.

To read a companion newsletter click here

Clinical Perspective: New AEs from Newer ART

Volume 4, Issue 8

While newer antiviral agents like darunavir and the integrase strand transfer inhibitor (INSTI) dolutegravir have shown great efficacy, recent postmarketing surveillance has identified important adverse effects not found in the clinical trial populations.

In this issue, Dr. Cody Chastain from the Division of Infectious Diseases at Vanderbilt University Medical Center discusses how these new findings can impact the clinical use of these new agents.

Take our post-test to claim CME credits.

To read a companion newsletter click here